Six months' course and outcome of metabolic abnormalities in a cohort of patients with schizophrenia in rural India

Metabolic Syndrome (MetS) is a frequently encountered serious adverse outcome in the treatment of schizophrenia (De Hert et al., 2008). A meta-analysis of worldwide studies estimated the overall prevalence of MetS as 33.4% (Vancampfort et al., 2015). We noted a similar pooled prevalence of 33.05% from hospital-based studies in India, but a much lower estimate of 10.81% in the studies done in rural communities (Ganesh et al., 2016). We recently reported that prevalence of MetS in schizophrenia in a rural community was comparable to that of general population (Rawat et al).

Source: Schizophrenia Research - June 4, 2018 Category: Psychiatry Authors: Somashekar Bijjal, Suhas Ganesh, Vikram Singh Rawat, Vikas Agarwal, K. Shanivaram Reddy, N.R. Renuka Devi, Chennaveerachari Naveen Kumar, Rita Christopher, Jagadisha Thirthalli Tags: Letter to the Editor Source Type: research